R&D Trends

Pfizer launches competitive grants program for cardiovascular disease research

Friday, April 10, 2015 01:21 PM

Pfizer has launched a new competitive grants program to support research projects investigating the role of Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) in health and cardiovascular disease. This competitive grants program, which is an extension of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Cardiovascular program, is part of Pfizer's ongoing commitment to translate scientific discoveries into innovative medicines for patients with cardiovascular disease.

More... »


Sanford-Burnham, Daiichi Sankyo ink agreement

Thursday, April 9, 2015 01:48 PM

Sanford-Burnham Medical Research Institute, a nonprofit, independent institute that employs more than 1,000 scientists and staff in San Diego, Calif., and Orlando, Fla., has signed a licensing agreement to further develop a first-in-class small molecule with Daiichi Sankyo for the treatment of cardiovascular-metabolic disease.

More... »


DARPA awards Inovio $45M Ebola program grant

Thursday, April 9, 2015 01:43 PM

Inovio Pharmaceuticals, based in Plymouth Meeting, Pa., has been awarded a $45 million grant from the Defense Advanced Research Projects Agency (DARPA) to lead a collaborative team to develop multiple treatment and prevention approaches against Ebola.

More... »

Bristol-Myers Squibb, uniQure collaborate on gene therapies for cardiovascular diseases

Wednesday, April 8, 2015 01:03 PM

Bristol-Myers Squibb has inked an agreement with uniQure, a gene therapy developer based in the Netherlands, for exclusive access to uniQure’s gene therapy technology platform for multiple targets in cardiovascular diseases.

More... »

National MS Society invests $28M in MS research

Wednesday, April 8, 2015 12:55 PM

The National Multiple Sclerosis Society has committed $28 million to support an expected 84 new multiple sclerosis (MS) research projects and training awards. These are part of a comprehensive research strategy aimed at stopping MS, restoring function that has been lost and ending the disease.

More... »

CRISPR Therapeutics to establish R&D operations in Massachusetts

Wednesday, April 8, 2015 12:42 PM

CRISPR Therapeutics, a Switzerland-based biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines for serious human diseases, has appointed Bill Lundberg, M.D., to chief scientific officer to lead the company's development programs and to spearhead the creation of its R&D operations in Cambridge, Mass.

More... »

Arvinas, Merck to collaborate

Wednesday, April 8, 2015 12:41 PM

Arvinas, a New Haven, Conn.-based private biotechnology company creating a new class of drugs based on protein degradation, has formed a strategic collaboration with Merck in which Arvinas' novel PROTAC technology will be used to degrade target proteins to create novel therapeutics. The multi-year collaboration will encompass multiple disease targets across several therapeutic areas.

More... »

Report: 9 out of 10 pharma companies have dedicated health economics, outcomes research groups

Monday, April 6, 2015 12:00 PM

Dedicated health economics and outcomes research (HEOR) teams that develop data to demonstrate a cohesive value proposition to payers are a vital part of a successful managed markets strategy, according to a new report by life sciences intelligence firm Cutting Edge Information.

More... »

Cannabics Pharmaceuticals, Technion Institute ink agreement

Monday, April 6, 2015 11:58 AM

Cannabics Pharmaceuticals, based in Bethesda, Md., has inked a research agreement with the Israel Institute of Technology (Technion) in Israel, for the screening of potential anticancer cannabinoid compounds.

More... »

Sanofi, Schrödinger ink $120M drug design pact

Friday, April 3, 2015 01:39 PM

Schrödinger, a global provider of advanced molecular simulations and enterprise software solutions and services for life sciences and materials research, has entered into a collaboration with Sanofi in which Schrödinger will provide comprehensive computational drug design support, from target analysis and validation to lead identification and lead optimization, for as many as ten drug discovery programs. Schrödinger could receive up to $120 million under the terms of the broad, multi-year relationship that includes preclinical milestones.

More... »

CenterWatch
CWWeekly

May 18

Research for All Act reaches Congress for second time seeking gender equality in basic research, clinical trials

MediciGlobal finds fewer trial dropouts among participants who actively pursue enrollment versus those recruited

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs